Latest Proteomics International Laboratories (ASX:PIQ) News

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

New data reveals that Thoroughbred racehorses free from oxidative stress are significantly more likely to win or place, spotlighting OxiDx’s patented biomarker test as a game-changer in equine performance and welfare.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Proteomics International Laboratories has secured ISO 15189 certification and launched PromarkerD and PromarkerEso nationally in Australia, while advancing US reimbursement pathways and preparing for leadership transition.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.

Proteomics International Laboratories announces the planned retirement of its founder and Managing Director, Dr Richard Lipscombe, in February 2026, marking a pivotal leadership transition as the company seeks a new CEO to drive its next growth phase.

Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.